 Helen S. Te
Concepts (333)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Liver Transplantation | 30 | 2021 | 1251 | 4.130 |
Why?
| | Liver Cirrhosis | 12 | 2017 | 258 | 2.350 |
Why?
| | Hepatitis C, Chronic | 7 | 2019 | 120 | 1.630 |
Why?
| | Antiviral Agents | 12 | 2019 | 507 | 1.630 |
Why?
| | Hepatitis C | 7 | 2013 | 209 | 1.490 |
Why?
| | Tissue Donors | 6 | 2021 | 442 | 1.360 |
Why?
| | Immunosuppressive Agents | 10 | 2017 | 1028 | 1.240 |
Why?
| | Hepacivirus | 7 | 2019 | 152 | 1.140 |
Why?
| | Liver Failure | 3 | 2019 | 82 | 0.990 |
Why?
| | Hepatitis, Autoimmune | 2 | 2016 | 19 | 0.900 |
Why?
| | Viral Load | 3 | 2019 | 143 | 0.830 |
Why?
| | Liver Diseases | 5 | 2021 | 228 | 0.800 |
Why?
| | End Stage Liver Disease | 3 | 2017 | 52 | 0.780 |
Why?
| | Liver Neoplasms | 7 | 2021 | 640 | 0.750 |
Why?
| | Intestinal Polyps | 1 | 2018 | 26 | 0.740 |
Why?
| | Duodenal Diseases | 1 | 2018 | 23 | 0.740 |
Why?
| | Stomach Diseases | 1 | 2018 | 23 | 0.740 |
Why?
| | Hypertension, Portal | 1 | 2018 | 46 | 0.730 |
Why?
| | Gastric Mucosa | 1 | 2018 | 71 | 0.710 |
Why?
| | Ribavirin | 5 | 2016 | 59 | 0.700 |
Why?
| | Rifamycins | 1 | 2016 | 5 | 0.660 |
Why?
| | Hepatorenal Syndrome | 1 | 2016 | 8 | 0.660 |
Why?
| | Heart Transplantation | 4 | 2021 | 672 | 0.650 |
Why?
| | Anti-Infective Agents | 1 | 2016 | 109 | 0.600 |
Why?
| | Deficiency Diseases | 1 | 2015 | 9 | 0.590 |
Why?
| | Organ Transplantation | 1 | 2019 | 281 | 0.590 |
Why?
| | Hepatic Veno-Occlusive Disease | 1 | 2014 | 18 | 0.560 |
Why?
| | Zinc | 1 | 2015 | 95 | 0.560 |
Why?
| | Practice Guidelines as Topic | 3 | 2019 | 1088 | 0.560 |
Why?
| | Middle Aged | 36 | 2021 | 25702 | 0.550 |
Why?
| | Liver Failure, Acute | 1 | 2014 | 38 | 0.550 |
Why?
| | Carcinoma, Hepatocellular | 5 | 2021 | 322 | 0.520 |
Why?
| | Male | 44 | 2021 | 42140 | 0.510 |
Why?
| | Hepatitis E | 1 | 2013 | 10 | 0.510 |
Why?
| | Humans | 62 | 2022 | 84199 | 0.510 |
Why?
| | Kidney Transplantation | 3 | 2022 | 835 | 0.500 |
Why?
| | Acute Kidney Injury | 1 | 2016 | 274 | 0.490 |
Why?
| | Graft Survival | 6 | 2020 | 887 | 0.490 |
Why?
| | Monitoring, Immunologic | 1 | 2012 | 17 | 0.480 |
Why?
| | Interferon-alpha | 3 | 2011 | 240 | 0.480 |
Why?
| | Graft Rejection | 5 | 2016 | 1112 | 0.480 |
Why?
| | Postoperative Complications | 6 | 2019 | 2280 | 0.470 |
Why?
| | Immunocompromised Host | 1 | 2013 | 144 | 0.470 |
Why?
| | Hospitals | 2 | 2021 | 212 | 0.470 |
Why?
| | Donor Selection | 1 | 2012 | 66 | 0.460 |
Why?
| | Female | 41 | 2022 | 45032 | 0.460 |
Why?
| | Portasystemic Shunt, Transjugular Intrahepatic | 2 | 2018 | 37 | 0.410 |
Why?
| | Tissue and Organ Procurement | 2 | 2019 | 293 | 0.400 |
Why?
| | Biopsy | 5 | 2018 | 1189 | 0.400 |
Why?
| | Hepatitis B | 1 | 2010 | 78 | 0.390 |
Why?
| | CD4-Positive T-Lymphocytes | 1 | 2012 | 401 | 0.390 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2014 | 673 | 0.370 |
Why?
| | Marfan Syndrome | 1 | 2007 | 30 | 0.340 |
Why?
| | Hernia, Hiatal | 1 | 2007 | 27 | 0.340 |
Why?
| | Gastroenterology | 2 | 2021 | 125 | 0.330 |
Why?
| | Endoscopy, Digestive System | 1 | 2007 | 79 | 0.330 |
Why?
| | Aged | 20 | 2022 | 18611 | 0.330 |
Why?
| | Polyethylene Glycols | 2 | 2010 | 393 | 0.320 |
Why?
| | Adult | 24 | 2021 | 26137 | 0.310 |
Why?
| | Liver Cirrhosis, Biliary | 2 | 2003 | 30 | 0.310 |
Why?
| | Hepatitis B, Chronic | 2 | 2016 | 35 | 0.300 |
Why?
| | Liver | 4 | 2017 | 1260 | 0.290 |
Why?
| | Guanine | 2 | 2016 | 208 | 0.290 |
Why?
| | Cimicifuga | 1 | 2004 | 3 | 0.290 |
Why?
| | Follow-Up Studies | 7 | 2021 | 3883 | 0.290 |
Why?
| | Mycophenolic Acid | 1 | 2005 | 84 | 0.290 |
Why?
| | Treatment Outcome | 15 | 2022 | 7966 | 0.280 |
Why?
| | Hepatitis | 3 | 2001 | 32 | 0.280 |
Why?
| | Retrospective Studies | 14 | 2017 | 7798 | 0.280 |
Why?
| | Cyclosporine | 2 | 2003 | 254 | 0.270 |
Why?
| | Cholestasis | 1 | 2004 | 49 | 0.260 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2014 | 2332 | 0.260 |
Why?
| | Hypophosphatemia | 1 | 2003 | 11 | 0.260 |
Why?
| | Phytotherapy | 1 | 2004 | 135 | 0.250 |
Why?
| | United States | 10 | 2022 | 6396 | 0.250 |
Why?
| | Phosphorus | 1 | 2003 | 138 | 0.250 |
Why?
| | Streptococcus | 1 | 2002 | 13 | 0.250 |
Why?
| | Plant Extracts | 1 | 2004 | 247 | 0.240 |
Why?
| | Streptococcal Infections | 1 | 2002 | 65 | 0.230 |
Why?
| | Risk Factors | 8 | 2022 | 5454 | 0.230 |
Why?
| | Genotype | 4 | 2013 | 1858 | 0.220 |
Why?
| | Fistula | 1 | 2021 | 41 | 0.220 |
Why?
| | Bacteremia | 1 | 2002 | 118 | 0.220 |
Why?
| | Incidence | 5 | 2022 | 1652 | 0.220 |
Why?
| | Folic Acid Antagonists | 1 | 2000 | 20 | 0.220 |
Why?
| | Foreign-Body Migration | 1 | 2001 | 38 | 0.220 |
Why?
| | Hepatitis, Alcoholic | 1 | 2020 | 18 | 0.210 |
Why?
| | Gilbert Disease | 1 | 2000 | 1 | 0.210 |
Why?
| | Liver Diseases, Alcoholic | 1 | 2020 | 21 | 0.210 |
Why?
| | Job Satisfaction | 1 | 2021 | 71 | 0.210 |
Why?
| | Heart Failure | 3 | 2019 | 1114 | 0.210 |
Why?
| | RNA, Viral | 4 | 2017 | 345 | 0.210 |
Why?
| | Internship and Residency | 2 | 2021 | 921 | 0.200 |
Why?
| | Methotrexate | 1 | 2000 | 264 | 0.200 |
Why?
| | Alanine Transaminase | 2 | 2013 | 79 | 0.200 |
Why?
| | Cholestasis, Intrahepatic | 1 | 1999 | 21 | 0.200 |
Why?
| | Internal Medicine | 2 | 2021 | 350 | 0.200 |
Why?
| | Burnout, Professional | 1 | 2021 | 79 | 0.200 |
Why?
| | Neoplasms, Second Primary | 1 | 2002 | 251 | 0.200 |
Why?
| | Autoimmune Diseases | 2 | 2001 | 236 | 0.200 |
Why?
| | Liver Function Tests | 2 | 2013 | 99 | 0.200 |
Why?
| | Curriculum | 2 | 2021 | 481 | 0.190 |
Why?
| | Isoenzymes | 1 | 2000 | 277 | 0.190 |
Why?
| | Multiple Organ Failure | 1 | 2019 | 44 | 0.190 |
Why?
| | Hepatic Encephalopathy | 1 | 1999 | 30 | 0.190 |
Why?
| | Embolization, Therapeutic | 1 | 2021 | 229 | 0.190 |
Why?
| | Drug Therapy, Combination | 6 | 2016 | 994 | 0.190 |
Why?
| | Glucuronosyltransferase | 1 | 2000 | 188 | 0.180 |
Why?
| | Stents | 1 | 2001 | 386 | 0.180 |
Why?
| | Severity of Illness Index | 3 | 2017 | 1784 | 0.180 |
Why?
| | Opiate Substitution Treatment | 1 | 2017 | 16 | 0.180 |
Why?
| | Heart Defects, Congenital | 1 | 2021 | 352 | 0.180 |
Why?
| | Q Fever | 1 | 2017 | 8 | 0.170 |
Why?
| | Hypertension, Pulmonary | 1 | 2022 | 345 | 0.170 |
Why?
| | Time Factors | 5 | 2017 | 5516 | 0.170 |
Why?
| | Patient Selection | 2 | 2020 | 701 | 0.170 |
Why?
| | Fluorenes | 1 | 2016 | 8 | 0.170 |
Why?
| | Uridine Monophosphate | 1 | 2016 | 8 | 0.170 |
Why?
| | Midodrine | 1 | 2016 | 5 | 0.160 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2018 | 173 | 0.160 |
Why?
| | Fatal Outcome | 2 | 2014 | 308 | 0.160 |
Why?
| | Paracentesis | 1 | 2016 | 9 | 0.160 |
Why?
| | Students, Medical | 1 | 2021 | 350 | 0.160 |
Why?
| | Odds Ratio | 2 | 2016 | 684 | 0.160 |
Why?
| | Vasoconstrictor Agents | 1 | 2016 | 53 | 0.160 |
Why?
| | Proportional Hazards Models | 2 | 2016 | 875 | 0.160 |
Why?
| | Recurrence | 4 | 2016 | 1200 | 0.160 |
Why?
| | Ascites | 1 | 2016 | 57 | 0.160 |
Why?
| | Cardiac Surgical Procedures | 1 | 2001 | 470 | 0.150 |
Why?
| | Health Policy | 1 | 2017 | 171 | 0.150 |
Why?
| | Multidetector Computed Tomography | 1 | 2016 | 57 | 0.150 |
Why?
| | HIV Infections | 1 | 2004 | 727 | 0.150 |
Why?
| | Benzimidazoles | 1 | 2016 | 137 | 0.150 |
Why?
| | Hospitalization | 3 | 2016 | 778 | 0.150 |
Why?
| | Risk Assessment | 3 | 2017 | 2295 | 0.150 |
Why?
| | Societies, Medical | 1 | 2019 | 579 | 0.150 |
Why?
| | Macrocyclic Compounds | 1 | 2014 | 7 | 0.150 |
Why?
| | Young Adult | 6 | 2021 | 6007 | 0.140 |
Why?
| | Survival Rate | 2 | 2021 | 1925 | 0.140 |
Why?
| | Kaplan-Meier Estimate | 2 | 2015 | 902 | 0.140 |
Why?
| | Carbamates | 1 | 2014 | 20 | 0.140 |
Why?
| | Gastrointestinal Diseases | 1 | 2016 | 150 | 0.140 |
Why?
| | Comorbidity | 2 | 2017 | 943 | 0.140 |
Why?
| | Polycystic Kidney, Autosomal Dominant | 1 | 2016 | 132 | 0.140 |
Why?
| | Hepatitis B virus | 2 | 2015 | 39 | 0.140 |
Why?
| | Esophagitis | 1 | 2014 | 42 | 0.140 |
Why?
| | Anilides | 1 | 2014 | 48 | 0.140 |
Why?
| | Early Diagnosis | 1 | 2015 | 130 | 0.140 |
Why?
| | Multivariate Analysis | 2 | 2015 | 1015 | 0.140 |
Why?
| | Statistics, Nonparametric | 1 | 2015 | 326 | 0.140 |
Why?
| | Autoantibodies | 2 | 2014 | 261 | 0.130 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2014 | 102 | 0.130 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 194 | 0.130 |
Why?
| | Crohn Disease | 1 | 2000 | 733 | 0.130 |
Why?
| | Career Choice | 3 | 2021 | 146 | 0.130 |
Why?
| | ABO Blood-Group System | 1 | 2014 | 66 | 0.130 |
Why?
| | Colitis, Ulcerative | 1 | 2000 | 704 | 0.130 |
Why?
| | Linear Models | 1 | 2015 | 431 | 0.130 |
Why?
| | Skin Neoplasms | 1 | 1999 | 545 | 0.130 |
Why?
| | Prognosis | 3 | 2021 | 3729 | 0.130 |
Why?
| | Cohort Studies | 3 | 2016 | 2731 | 0.130 |
Why?
| | Melanoma | 1 | 1999 | 517 | 0.130 |
Why?
| | Hepatitis E virus | 1 | 2013 | 7 | 0.130 |
Why?
| | Radiographic Image Enhancement | 1 | 2016 | 467 | 0.130 |
Why?
| | Roseolovirus Infections | 1 | 2013 | 7 | 0.130 |
Why?
| | Herpesvirus 6, Human | 1 | 2013 | 19 | 0.130 |
Why?
| | Aspartate Aminotransferases | 1 | 2013 | 72 | 0.130 |
Why?
| | Analgesics, Opioid | 1 | 2017 | 381 | 0.130 |
Why?
| | Ganciclovir | 1 | 2013 | 57 | 0.130 |
Why?
| | Radiation Injuries | 1 | 2014 | 159 | 0.130 |
Why?
| | Liver Cirrhosis, Alcoholic | 1 | 2012 | 20 | 0.130 |
Why?
| | Isoantibodies | 1 | 2014 | 123 | 0.120 |
Why?
| | Cooperative Behavior | 1 | 2014 | 170 | 0.120 |
Why?
| | Sirolimus | 1 | 2014 | 173 | 0.120 |
Why?
| | Disease Progression | 2 | 2015 | 1481 | 0.120 |
Why?
| | Transplantation, Homologous | 3 | 2021 | 1022 | 0.120 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2016 | 464 | 0.120 |
Why?
| | HLA Antigens | 1 | 2014 | 228 | 0.120 |
Why?
| | Hospitalists | 1 | 2014 | 122 | 0.120 |
Why?
| | Aged, 80 and over | 4 | 2016 | 6605 | 0.120 |
Why?
| | DNA, Viral | 1 | 2013 | 282 | 0.120 |
Why?
| | Immunoassay | 1 | 2012 | 94 | 0.120 |
Why?
| | Case-Control Studies | 1 | 2016 | 1833 | 0.110 |
Why?
| | Immunity, Cellular | 1 | 2012 | 191 | 0.110 |
Why?
| | Fatty Liver | 1 | 2012 | 123 | 0.110 |
Why?
| | Recombinant Proteins | 3 | 2011 | 1067 | 0.110 |
Why?
| | Living Donors | 1 | 2014 | 308 | 0.110 |
Why?
| | Quality of Health Care | 1 | 2014 | 367 | 0.110 |
Why?
| | Obesity | 1 | 2017 | 975 | 0.100 |
Why?
| | Molecular Epidemiology | 1 | 2010 | 59 | 0.100 |
Why?
| | Mass Screening | 1 | 2015 | 626 | 0.100 |
Why?
| | Biliary Fistula | 1 | 2009 | 8 | 0.100 |
Why?
| | Respiratory Tract Fistula | 1 | 2009 | 9 | 0.100 |
Why?
| | Neoplasms | 1 | 2004 | 2725 | 0.090 |
Why?
| | Toxocariasis | 1 | 2008 | 3 | 0.090 |
Why?
| | Chronic Disease | 3 | 2016 | 978 | 0.090 |
Why?
| | Gastroscopy | 1 | 2007 | 22 | 0.090 |
Why?
| | Adolescent | 5 | 2019 | 9210 | 0.090 |
Why?
| | Aortic Rupture | 1 | 2007 | 53 | 0.080 |
Why?
| | Waiting Lists | 2 | 2019 | 163 | 0.080 |
Why?
| | Anti-Inflammatory Agents | 2 | 2001 | 342 | 0.080 |
Why?
| | Esophagoscopy | 1 | 2007 | 116 | 0.080 |
Why?
| | Hepatitis B e Antigens | 2 | 2016 | 8 | 0.080 |
Why?
| | Amantadine | 1 | 2005 | 18 | 0.070 |
Why?
| | Retreatment | 1 | 2005 | 106 | 0.070 |
Why?
| | Cardiovascular Diseases | 1 | 2012 | 819 | 0.070 |
Why?
| | Hot Flashes | 1 | 2004 | 12 | 0.070 |
Why?
| | Hemoglobins | 1 | 2005 | 176 | 0.070 |
Why?
| | Prevalence | 2 | 2021 | 1272 | 0.070 |
Why?
| | Prednisone | 2 | 2003 | 264 | 0.070 |
Why?
| | Hospital Costs | 2 | 2016 | 103 | 0.070 |
Why?
| | Complementary Therapies | 1 | 2004 | 53 | 0.070 |
Why?
| | Logistic Models | 3 | 2012 | 1166 | 0.070 |
Why?
| | Biopsy, Needle | 1 | 2004 | 268 | 0.070 |
Why?
| | Bile Ducts | 1 | 2003 | 62 | 0.060 |
Why?
| | Clinical Competence | 2 | 2021 | 712 | 0.060 |
Why?
| | Arthroplasty, Replacement, Knee | 1 | 2005 | 108 | 0.060 |
Why?
| | Arthroplasty, Replacement, Hip | 1 | 2005 | 129 | 0.060 |
Why?
| | Chickenpox Vaccine | 1 | 2002 | 8 | 0.060 |
Why?
| | Arthroplasty, Replacement | 1 | 2003 | 39 | 0.060 |
Why?
| | Drug Administration Schedule | 2 | 2003 | 973 | 0.060 |
Why?
| | Monitoring, Physiologic | 1 | 2004 | 285 | 0.060 |
Why?
| | Chickenpox | 1 | 2002 | 42 | 0.060 |
Why?
| | Glucocorticoids | 2 | 2003 | 362 | 0.060 |
Why?
| | Pilot Projects | 1 | 2005 | 838 | 0.060 |
Why?
| | Tacrolimus | 1 | 2003 | 385 | 0.060 |
Why?
| | Polymerase Chain Reaction | 2 | 2017 | 1000 | 0.060 |
Why?
| | Yttrium Radioisotopes | 1 | 2021 | 33 | 0.060 |
Why?
| | Recovery of Function | 1 | 2003 | 264 | 0.060 |
Why?
| | Salaries and Fringe Benefits | 1 | 2021 | 21 | 0.060 |
Why?
| | Training Support | 1 | 2021 | 25 | 0.050 |
Why?
| | Bilirubin | 1 | 2021 | 129 | 0.050 |
Why?
| | Hyperbilirubinemia | 1 | 2000 | 21 | 0.050 |
Why?
| | Medicine | 1 | 2021 | 74 | 0.050 |
Why?
| | Cholangitis | 1 | 1999 | 23 | 0.050 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1830 | 0.050 |
Why?
| | Educational Measurement | 1 | 2021 | 209 | 0.050 |
Why?
| | Diabetes Complications | 1 | 2021 | 222 | 0.050 |
Why?
| | Transition to Adult Care | 1 | 2019 | 21 | 0.050 |
Why?
| | Medicare | 1 | 2022 | 292 | 0.050 |
Why?
| | Radiography, Thoracic | 1 | 2001 | 324 | 0.050 |
Why?
| | Physician's Role | 1 | 2021 | 187 | 0.050 |
Why?
| | Cytomegalovirus Infections | 1 | 1999 | 158 | 0.050 |
Why?
| | Child, Preschool | 2 | 2019 | 3788 | 0.050 |
Why?
| | Registries | 1 | 2022 | 675 | 0.040 |
Why?
| | Academic Medical Centers | 1 | 2021 | 395 | 0.040 |
Why?
| | Methylprednisolone | 1 | 1997 | 75 | 0.040 |
Why?
| | Doxycycline | 1 | 2017 | 33 | 0.040 |
Why?
| | Predictive Value of Tests | 1 | 2003 | 1774 | 0.040 |
Why?
| | Risk | 1 | 2019 | 701 | 0.040 |
Why?
| | Patient Compliance | 1 | 2019 | 249 | 0.040 |
Why?
| | Histocytochemistry | 1 | 2017 | 137 | 0.040 |
Why?
| | Adiposity | 1 | 2017 | 72 | 0.040 |
Why?
| | Necrosis | 1 | 1997 | 207 | 0.040 |
Why?
| | Tomography, X-Ray Computed | 1 | 2007 | 2585 | 0.040 |
Why?
| | Azathioprine | 1 | 1997 | 126 | 0.040 |
Why?
| | Risk Reduction Behavior | 1 | 2017 | 108 | 0.040 |
Why?
| | Nutrition Surveys | 1 | 2017 | 91 | 0.040 |
Why?
| | Alleles | 1 | 2000 | 1119 | 0.040 |
Why?
| | Drug Combinations | 1 | 2016 | 245 | 0.040 |
Why?
| | Cost Savings | 1 | 2016 | 62 | 0.040 |
Why?
| | Hepatitis B Surface Antigens | 1 | 2015 | 27 | 0.040 |
Why?
| | Animals | 2 | 2013 | 27167 | 0.040 |
Why?
| | Weight Loss | 1 | 2017 | 240 | 0.040 |
Why?
| | Quality Improvement | 1 | 2019 | 370 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2019 | 394 | 0.040 |
Why?
| | 2-Naphthylamine | 1 | 2014 | 1 | 0.040 |
Why?
| | Lactams, Macrocyclic | 1 | 2014 | 16 | 0.040 |
Why?
| | Cyclopropanes | 1 | 2014 | 29 | 0.040 |
Why?
| | Ritonavir | 1 | 2014 | 14 | 0.040 |
Why?
| | Quality Indicators, Health Care | 1 | 2016 | 133 | 0.040 |
Why?
| | Proline | 1 | 2014 | 55 | 0.040 |
Why?
| | Health Status | 1 | 2017 | 366 | 0.040 |
Why?
| | Pediatrics | 1 | 2019 | 349 | 0.040 |
Why?
| | Bariatric Surgery | 1 | 2017 | 195 | 0.040 |
Why?
| | Uracil | 1 | 2014 | 68 | 0.040 |
Why?
| | Valine | 1 | 2014 | 77 | 0.030 |
Why?
| | Viral Nonstructural Proteins | 1 | 2014 | 40 | 0.030 |
Why?
| | Child | 2 | 2019 | 6847 | 0.030 |
Why?
| | Plasmapheresis | 1 | 2014 | 31 | 0.030 |
Why?
| | Observer Variation | 1 | 2016 | 622 | 0.030 |
Why?
| | Transaminases | 1 | 2014 | 37 | 0.030 |
Why?
| | Complement C4b | 1 | 2014 | 34 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2016 | 411 | 0.030 |
Why?
| | Spouses | 1 | 2014 | 34 | 0.030 |
Why?
| | Hospital Mortality | 1 | 2016 | 333 | 0.030 |
Why?
| | Immunoglobulins, Intravenous | 1 | 2014 | 64 | 0.030 |
Why?
| | Histocompatibility Testing | 1 | 2014 | 158 | 0.030 |
Why?
| | Body Mass Index | 1 | 2017 | 787 | 0.030 |
Why?
| | Fractures, Bone | 2 | 2005 | 118 | 0.030 |
Why?
| | Heart Block | 1 | 2012 | 45 | 0.030 |
Why?
| | Length of Stay | 1 | 2016 | 705 | 0.030 |
Why?
| | Infant | 1 | 2019 | 3136 | 0.030 |
Why?
| | Prospective Studies | 1 | 2021 | 4122 | 0.030 |
Why?
| | Databases, Factual | 1 | 2016 | 801 | 0.030 |
Why?
| | Sulfonamides | 1 | 2014 | 330 | 0.030 |
Why?
| | Guideline Adherence | 1 | 2014 | 226 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2014 | 482 | 0.030 |
Why?
| | Anti-Bacterial Agents | 1 | 2017 | 825 | 0.030 |
Why?
| | Dyslipidemias | 1 | 2012 | 120 | 0.030 |
Why?
| | Inpatients | 1 | 2014 | 277 | 0.030 |
Why?
| | Sensitivity and Specificity | 1 | 2016 | 2082 | 0.030 |
Why?
| | Arrhythmias, Cardiac | 1 | 2012 | 212 | 0.030 |
Why?
| | Neuroblastoma | 1 | 2014 | 369 | 0.030 |
Why?
| | Treatment Failure | 1 | 2010 | 303 | 0.030 |
Why?
| | Obesity, Morbid | 1 | 2012 | 211 | 0.030 |
Why?
| | Cholangiopancreatography, Magnetic Resonance | 1 | 2009 | 8 | 0.020 |
Why?
| | Drug Carriers | 1 | 2010 | 150 | 0.020 |
Why?
| | Heart Arrest | 1 | 2012 | 265 | 0.020 |
Why?
| | Myocardial Infarction | 1 | 2012 | 378 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2016 | 2685 | 0.020 |
Why?
| | Thoracotomy | 1 | 2009 | 59 | 0.020 |
Why?
| | Cholangiopancreatography, Endoscopic Retrograde | 1 | 2009 | 78 | 0.020 |
Why?
| | Mutation | 1 | 2000 | 3885 | 0.020 |
Why?
| | B-Lymphocytes | 1 | 2014 | 795 | 0.020 |
Why?
| | Cats | 1 | 2008 | 305 | 0.020 |
Why?
| | Cadaver | 1 | 2007 | 186 | 0.020 |
Why?
| | Tissue and Organ Harvesting | 1 | 2007 | 80 | 0.020 |
Why?
| | T-Lymphocytes | 1 | 2014 | 1304 | 0.020 |
Why?
| | Hepatectomy | 1 | 2007 | 158 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 1207 | 0.020 |
Why?
| | Emergencies | 1 | 2005 | 113 | 0.020 |
Why?
| | Stroke | 1 | 2012 | 802 | 0.020 |
Why?
| | Survival Analysis | 1 | 2007 | 1591 | 0.020 |
Why?
| | Hypertension | 1 | 2012 | 1215 | 0.020 |
Why?
| | Osteonecrosis | 1 | 2003 | 23 | 0.020 |
Why?
| | Arthritis | 1 | 2003 | 45 | 0.020 |
Why?
| | Acyclovir | 1 | 2002 | 109 | 0.010 |
Why?
| | Postoperative Period | 1 | 2003 | 312 | 0.010 |
Why?
| | Hepatitis Antibodies | 1 | 2001 | 8 | 0.010 |
Why?
| | Adrenal Cortex Hormones | 1 | 2003 | 266 | 0.010 |
Why?
| | Interferons | 1 | 2001 | 130 | 0.010 |
Why?
| | Syndrome | 1 | 2001 | 436 | 0.010 |
Why?
|
|
Te's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|